IDEAYA Biosciences, Inc. IDYA Business Segments
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| External Clinical Development Expenses by Product | ||||
| Darovasertib | $98.24M+48.4% | $66.2M+156% | $25.83M+92.3% | |
| IDE161 | $7.6M-38.9% | $12.44M+75.1% | $7.1M+158% | |
| IDE397 | $14.66M-25.0% | $19.56M+63.2% | $11.99M+27.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does IDEAYA Biosciences, Inc. break its business down?
- IDEAYA Biosciences, Inc. (IDYA) reports external clinical development expenses by product across 7 parts — Darovasertib, IDE034, IDE161, IDE397 and IDE574. Each is extracted from the segment footnotes and tracked over time.
- Where does IDEAYA Biosciences, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in IDEAYA Biosciences, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
